Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $216,075.48 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the transaction, the chief operating officer now directly owns 69,266 shares of the company’s stock, valued at $6,581,655.32. The trade was a 3.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Christina Rossi also recently made the following trade(s):

• On Tuesday, January 21st, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $110.14, for a total transaction of $250,458.36.

Blueprint Medicines Stock Down 2.5 %

Shares of NASDAQ BPMC traded down $2.36 during midday trading on Wednesday, hitting $90.72. The company’s stock had a trading volume of 606,651 shares, compared to its average volume of 712,138. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The firm has a market capitalization of $5.80 billion, a price-to-earnings ratio of -84.00 and a beta of 0.58. The business’s fifty day simple moving average is $99.12 and its two-hundred day simple moving average is $93.97. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BPMC. Quarry LP acquired a new stake in Blueprint Medicines in the 3rd quarter valued at about $32,000. R Squared Ltd acquired a new stake in Blueprint Medicines in the fourth quarter valued at approximately $51,000. Headlands Technologies LLC purchased a new position in Blueprint Medicines in the fourth quarter worth approximately $65,000. Thematics Asset Management acquired a new position in Blueprint Medicines during the 4th quarter worth approximately $72,000. Finally, Covestor Ltd increased its position in shares of Blueprint Medicines by 62.7% in the 4th quarter. Covestor Ltd now owns 973 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 375 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 price objective on shares of Blueprint Medicines in a research note on Thursday, February 13th. Piper Sandler upped their price target on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Wolfe Research initiated coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They set an “outperform” rating on the stock. Morgan Stanley assumed coverage on Blueprint Medicines in a research note on Thursday, March 20th. They issued an “equal weight” rating and a $100.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $124.95.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.